Clinical trials: Fibrinogen
Hyperinsulinism
Phase II Long Term, Randomized Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism
OBJECTIVES: Evaluate the safety and efficacy of long term recombinant human insulin-like growth factor I in children with hyperinsulinism.
- Trial name
- NCT00004700
- Testing
- insulin-like growth factor I
- Volunteers
- 16 people
- Sponsor
- Children's Hospital of Philadelphia
Insulin-Like Growth Factor I
Study on Dynamic Changes of Serum IGF-1 Post-Cerebral Hemorrhage and Its Prognostic Correlation
The purpose of this study is to dynamically observe the dynamic changes of serum IGF-1 after intracerebral hemorrhage, explore the impact and correlation of serum IGF-1 with the severity of the patient's condition and prognosis…
- Trial name
- NCT07043504
- Volunteers
- 100 people
- Sponsor
- Shengjing Hospital
Tympanic Membrane Perforation
Repair of Tympanic Membrane Perforation Using Tachosil Under Local Anesthesia
Tympanic membrane perforations are common medical problem that encounters a lot of patients in all age groups. The gold standard for treatment of perforations is tympanic membrane closure procedure (tympanoplasty) which is done…
- Trial name
- NCT04428463
- Testing
- Tachosil, fascia and cartilage
- Volunteers
- 27 people
- Sponsor
- HaEmek Medical Center, Israel
Hypertrophic Cardiomyopathy, Left Ventricular Hypertrophy
Factors Contributing to Increased Left Ventricle Size in Patients With Abnormally Enlarged Hearts
The human heart is divided into four chambers. One of the four chambers, the left ventricle, is the chamber mainly responsible for pumping blood out of the heart into the circulation.
- Trial name
- NCT00001878
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Polytrauma, Traumatic Hemorrhage
Transfusion of Red Blood Cells, Tranexamic Acid and Fibrinogen Concentrate for Severe Trauma Hemorrhage at Pre-hospital Phase of Care.
This is a single-center, not-randomized, open-label, controlled pilot clinical trial. This study compares presence of Trauma Induced Coagulopathy (TIC) and acute traumatic hemorrhage treatment at pre-hospital phase of care with…
- Trial name
- PRETIC (NCT03780894)
- Testing
- Fibrinogen Concentrate (Human) 1 MG [RiaSTAP], Red blood cells concentrate, Tranexamic Acid
- Where
- Spain
- Volunteers
- 79 people
- Sponsor
- Banc de Sang i Teixits
Cardiac Complication During Procedure
Prospective Double Blinded Randomized Control Study of the Use of Fibrinogen in High-Risk Cardiac Surgery
The aim of the study is to show that first line treatment with concentrated fibrinogen has superiority over the conventional therapy with fresh frozen plasma (FFP), platelets, and cryoprecipitate in perioperative management of…
- Trial name
- NCT01623531
- Testing
- Fibrinogen
- Where
- Canada
- Volunteers
- 62 people
- Sponsor
- Nova Scotia Health Authority
Coronary Artery Disease, Percutaneous Coronary Intervention
Study of the Long-term Effects of P2Y12 Inhibitor Monotherapy and Coagulation Markers After Percutaneous Coronary Angioplasty.
Patients who undergo percutaneous coronary intervention (PCI) are commonly treated with antiplatelet therapy to prevent stent thrombosis and recurrence of events.
- Conditions
- Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndromes, Antiplatelet Therapy
- Trial name
- HI-TECH 2 (NCT07582835)
- Testing
- Clopidogrel, Ticagrelor, Prasugrel
- Where
- Switzerland
- Volunteers
- 355 people
- Sponsor
- Cardiocentro Ticino
Previous Diagnosis With a Complement-mediated Disease and/or With Clinical Manifestations Reasonably Associated With Complement Factor I Deficiency
Screening Study to Identify Patients With Complement Factor I Deficiencies
This is screening study to identify patients with Complement Factor I deficiencies. The primary objective is to identify participants with CFI deficiencies and assess the prevalence in the screened population.
- Trial name
- NCT05072912
- Where
- United States
- Volunteers
- 113 people
- Sponsor
- Catalyst Biosciences
Thyroid Associated Ophthalmopathies
The Safety and Efficacy of Sequential Hormone Therapy and IBI311 Therapy in Patients With Active Moderate to Severe TAO in the Initial Treatment.
Thyroid-associated ophthalmopathy (TAO) is an organ-specific autoimmune disease closely related to thyroid disease, which leads the incidence of orbital disease in adults and is the most common cause of diffuse toxic goiter…
- Trial name
- NCT07152340
- Testing
- IBI311, Glucocorticoids
- Where
- 2 sites in China
- Volunteers
- 64 people
- Sponsor
- Shanghai Changzheng Hospital
Hypofibrinogenemia
A Point-of-care Electrochemical-based Device for Rapid Detection of Fibrinogen on Type A Aortic Dissection Surgery
This study compares the results of the existing fibrinogen concentration monitoring technology to the Electrochemical-based device, a point-of-care and rapid method,using a small amount of extra blood obtained in Type A Aortic…
- Trial name
- NCT06434389
- Testing
- the Electrochemical-based device
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Proximal Aortic Dissection
Safety and Efficacy of Fibrinogen Concentrate in Aortic Arch Surgery Involving Moderate Hypothermic Circulatory Arrest
Bleeding is a common complication of cardiac surgery, especially aortic arch surgery involving moderate hypothermic circulatory arrest.
- Trial name
- SEFC (NCT02542306)
- Testing
- fibrinogen concentrate
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Hongjia Zhang
Postpartum Hemorrhage
A Program to Evaluate Riastap® and FIBTEM® for the Early Control and Treatment of Postpartum Hemorrhage (PERFECT PPH)
In this prospective, single-center, randomized, placebo-controlled, double-blind clinical trial, parturients with primary PPH are eligible for treatment with fibrinogen concentrate following both vaginal delivery and cesarean…
- Trial name
- PERFECT PPH (NCT02528708)
- Testing
- fibrinogen concentrate
- Sponsor
- Yale University
Colon Cancer, Rectal Cancer
A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab
The purpose of this study is to determine the value of adding IMC-A12 to irinotecan and cetuximab in participants with metastatic colorectal cancer (CRC).
- Trial name
- FC-4 (NCT00845039)
- Testing
- Cetuximab, Irinotecan, IMC-A12 (cixutumumab)
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Eli Lilly and Company
Cardiovascular Diseases, Dyslipidemias
Effects of Nattokinase on Inflammation and Cardiovascular Risk Markers in Patients With Dyslipidemia
The study aims to evaluate the effect of the nattokinase enzyme on inflammation and markers of cardiovascular risk in participants with dyslipidemia.
- Conditions
- Cardiovascular Diseases, Dyslipidemias, Inflammation
- Trial name
- NCT06183307
- Testing
- Nattokinase
- Where
- Brazil
- Volunteers
- 48 people
- Sponsor
- Universidade Federal Fluminense
Exanguination, Trauma Coagulopathy
Stability of Blood Clotting Products Stored in Emergency Ambulances Under Real-World Conditions
Emergency medical service (EMS) vehicles are exposed to a wide range of environmental conditions, including high temperatures during summer months.
- Trial name
- STABLE-EMS (NCT07646964)
- Where
- Austria
- Volunteers
- 2 people
- Sponsor
- Medical University of Graz
Interaction Between the GH/IGF-I System and the Immune-system
The Relationship Between the Growth Hormone (GH)- Insulin Like Growth Factor I (IGF-I) System and the Inflammatory System in Healthy Normal Persons
Observations in patients with growth hormone (GH)-disturbances have suggested that GH/IGF-I might have anti-inflammatory effects.
- Trial name
- NCT00969644
- Testing
- Somatropin, Pegvisomant
- Where
- Denmark
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Herlev Hospital
Insulin Resistance, Hyperglycemia
Study of Recombinant Human Insulin-Like Growth Factor I in Patients With Severe Insulin Resistance
OBJECTIVES: I. Determine the efficacy and toxic effects of recombinant human insulin-like growth factor I (rhIGF-I) on carbohydrate tolerance, insulin action, insulin secretion, hyperandrogenism, and hyperlipidemia in patients…
- Trial name
- NCT00004419
- Testing
- insulin-like growth factor I
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Beth Israel Deaconess Medical Center
Alzheimer Disease, Early Onset
A Study to Assess THN391 in Subjects With Alzheimer's Disease
This is a Phase 1b study to evaluate different doses of the drug and see whether a drug is safe and how it behaves in the body. THN391 has already been assessed in healthy people without Alzheimer's disease.
- Trial name
- NCT06814730
- Testing
- THN391
- Where
- 4 sites in Netherlands, United Kingdom
- Volunteers
- 19 people
- Sponsor
- Therini Bio, Inc.
Rare Bleeding Disorders
Rare Bleeding Disorders in the Netherlands
Rationale: Rare bleeding disorders (deficiency of fibrinogen, factor II, V, V\&VIII, VII, X, XI, XIII, α2-antiplasmin or plasminogen activator inhibitor 1) are not well defined with respect to their clinical phenotype, laboratory…
- Trial name
- RBIN (NCT03347591)
- Testing
- WES, Several assays
- Where
- 7 sites in Netherlands
- Volunteers
- 300 people
- Sponsor
- Radboud University Medical Center
Surgical Bleeding
Topical Raplixa for Surgical Bleeding in Children
The purpose of the study is to determine if Raplixa plus Gelfoam is better than Gelfoam alone in stopping mild to moderate bleeding in children having surgery.
- Trial name
- NCT02117349
- Testing
- Raplixa, Gelfoam, Rescue treatment
- Where
- 13 sites in United States
- Volunteers
- 55 people
- Sponsor
- Mallinckrodt